No Data
[Brokerage Focus] Guozheng International: Innovative drug companies and medical instruments companies are expected to continuously expand their market ceiling by going overseas.
Jingwu Financial News | Guozheng International reports that looking towards 2025, as the Federal Reserve begins a rate cut cycle, combined with the high premium rate of A-shares over H-shares, the cost-effectiveness of Hong Kong stocks is becoming more pronounced, leading to improved liquidity. For the Pharmaceutical Sector, with the continuous advancement of the "medical insurance + commercial insurance" model and policy support, the scale of the Industry is expected to further expand. The bank is Bullish on three major investment themes driven by innovation, overseas expansion, and compliance with policy development: 1. Innovation: Interest rate-sensitive Innovative Drugs and Medical Devices are expected to continue benefiting from improved liquidity. The bank believes that the main factors driving the development of Innovative Drugs in 2025 will be as follows: (1) Overseas expansion. Due to the pricing disparity between China and the United States.
Tempus hold (06880) plans to implement a restructuring.
Tempus hold (06880) announced that on November 4, 2024, the company (as the borrower), jointly...
Express News | Tempus Holdings - to Issue 392.9 Mln Subscription Shares at Price of HK$0.127 per Share
Express News | Tempus Holdings - Loan Made Available to Co for HK$11.25 Mln on Nov 4
Tempus hold (06880) and its professional advisors are preparing for the review by the listing review committee.
tempus hold (06880) announced that as of the date of this announcement, the company and its professional advisors are preparing for the listing review committee...
Tempus hold (06880.HK): The court hearing is set for January 23, 2025. Trading remains suspended.
On December 4, Gelonghui reported that Tempus Hold (06880.HK) announced that on November 4, 2024, it submitted an application to the High Court of Hong Kong to convene a meeting of the company's creditors to consider and approve (with or without modifications) the debt repayment arrangement plan proposed by the company, in accordance with section 670 of the Companies Ordinance (Cap. 622 of the Laws of Hong Kong). The court hearing is scheduled for January 23, 2025. The company will publish further announcements in due course to inform its shareholders and potential investors of the latest developments. Trading of shares remains suspended.
